Molecule for a Cure

Our passionate associates are dedicated to the discovery of biopharmaceutical drugs and improving the lives of patients.


Accelerate drug discovery

We provide a groundbreaking new system that enables pharmaceutical companies who are developing new antibody drugs to identify antibody candidates 6x faster and with a 10x greater probability of success.

Molcure represents high quality antibody and target discovery. With cutting edge technology in-house, Molcure is the partner of choice for therapeutic antibody discovery. At Molcure we combine a deep knowledge of NGS, bioinformatics and antibody biology with automated discovery system. The antibody discovery platform Abtracer delivers superior functional antibodies.

Value proposition


Possible to identify hit candidates against difficult target

  • Name
  • Opportunity

    Cost pressures and new pay-for-performance payer approaches are making demonstration of real-world outcomes as essential to the drug research and development (R&D) model as initial, premarket evidence. Tied to this trend R&D organizations have an opportunity to improve productivity using big data and analytical capabilities.

  • Developability

    There are multiple factors currently limiting the discovery and approval of new medicines. The low-hanging fruit has already been picked, and regulatory constraints have tightened, requiring new drugs to show an increased level of efficacy and safety while also displaying significant differentiation from treatments already available. In addition payers are beginning to demand that new, pricier drugs demonstrate that they’re worth it. At the same time the race to be first approved for novel therapies puts an even greater focus on the need to be more efficient in clinical development. These factors have created an urgent need to get more ROI from R&D.

  • Name
  • Name
  • Big-data analysis

    Big data is part of that solution. The evolution of data capture and analysis techniques allows for innovative solution development in which more goes into clinical trials and more comes out, without necessarily an increase in cost. Here the “more” going in is information and insight rather than time and volume of resource. The “more” coming out are the tangible results that leaders in the area are starting to achieve, including improved patient recruiting and selection, and decreased clinical trial timelines and costs.